You are here

Home » In-person courses » Publicacions

Publicacions

Pubmed: 

The last 100 publications:

  1. Koren TJ, Dugal J, Wang D, Beadnall H, Wang CT, Barnett Y, Calamante F, Montalban X, Oh J, Barnett MH. Spinal cord imaging in multiple sclerosis: from diagnosis to disease progression. J Neurol. 2026 Sep 30. PMID: 42821125

  2. Carvajal R, Marcialis C, Tur C, Otero-Romero S, Roos I, Pappolla A, Novak F, Cobo-Calvo A, Ariño H, Arrambide G, Bollo L, Casallas-Vanegas A, Castilló J, Comabella M, Driemeyer C, Elosua I, Fadrique C, Galán I, Grávalos M, La Puma D, Masot A, Midaglia L, Molina-Goicoechea M, Mongay-Ochoa N, Rodríguez-Acevedo B, Río J, Tagliani P, Vidal-Jordana A, Vilaseca-Jolonch A, Zabalza A, Pugliatti M, Sastre-Garriga J, Kalincik T, Montalban X, Tintore M. Age and treatment class modify inflammatory risk after disease-modifying therapy discontinuation in older people with MS. J Neurol Neurosurg Psychiatry. 2026 Sep 14. PMID: 42735930

  3. Bollo L, Vidal-Jordana A, Rodríguez-Acevedo B, Sceppacuercia S, Mongay-Ochoa N, Zancan V, Ajdinaj P, Braga N, Cabello S, Alberich M, Corral J, Auger C, Tintoré M, Montalban X, Pareto D, Moncho D, Rovira À, Sastre-Garriga J. Evaluation of the 2022 international consensus criteria for optic neuritis: the role of clinical features and visual evoked potentials. J Neurol. 2026 Sep 4. PMID: 42696026

  4. Fernández Ó, Montalban X, Arés A, Agüera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Caminero AB, Castillo-Triviño T, Costa-Frossard L, Eichau S, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Monreal E, Moral E, Oreja-Guevara C, Prieto JM, Romero-Pinel L, Rovira À, Rodríguez-Antigüedad A. [XVIII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2025 ECTRIMS Congress (Part I)]. Rev Neurol. 2026 Aug 14. PMID: 42689738

  5. Fernández Ó, Montalban X, Arés A, Agüera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Caminero AB, Castillo-Triviño T, Costa-Frossard L, Eichau S, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Monreal E, Moral E, Oreja-Guevara C, Prieto JM, Romero-Pinel L, Rovira À, Rodríguez-Antigüedad A. [XVIII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2025 ECTRIMS Congress (Part II)]. Rev Neurol. 2026 Aug 20. PMID: 42689737

  6. Morató X, Hinojosa-Calleja A, Jofresa S, Calm B, Cano A, Blazquez-Folch J, Alarcón-Martín E, Montrreal L, Muñoz-Morales Á, Olivé C, Bayón P, Sotolongo-Grau O, Orellana A, Sanz-Cartagena P, Montalban X, Marquié M, Fernandez MV, Ruiz A, Boada M, Valero S. When treatment becomes risk: polypharmacy and inappropriate prescribing in cognitive impairment in 2379 consecutive patients from a memory clinic. Alzheimers Dement. 2026 Aug. PMID: 42639919

  7. Montobbio N, Bovis F, Hofer L, Häring DA, Benkert P, Tur C, Kalincik T, Sharmin S, Masot Llima A, Hernández Soria D, Salter A, Morocz I, Wang Q, Kuhle J, Chappell S, Capra R, Cordioli C, D'Souza M, Coetzee T, Montalban X, Arnold DL, Calabresi PA, Sormani MP. A community-validated tool for clinical outcome calculation in multiple sclerosis: Consensus development and scenario-specific recommendations. Mult Scler. 2026 Aug 22. PMID: 42631555

  8. Villacieros-Álvarez J, Espejo C, Arrambide G, Castillo M, Rodriguez M, Ariño H, Elosua I, Tur C, Vidal-Jordana A, Vilaseca A, Castilló J, Galán I, Midaglia L, Nos C, Rodríguez-Acevedo B, Zabalza A, Bollo L, Pappolla A, Carvajal R, Mongay-Ochoa N, Rio J, Sastre-Garriga J, Comabella M, Busiello G, Sceppacuercia S, Rovira À, Montalban X, Tintoré M, Auger C, Cobo-Calvo Á. "Low-Positive" MOG-IgG Cases Among Adults With a First Event Suggestive of Multiple Sclerosis. Ann Clin Transl Neurol. 2026 Aug 21. PMID: 42630031

  9. Fernández V, Pappolla A, Carbonell-Mirabent P, Castillo M, Gutierrez L, Fissolo N, León Plaza O, Braga N, Ariño H, Auger C, Bollo L, Castilló J, Carvajal R, Cobo-Calvo A, Espejo C, Galan I, Guio-Sánchez C, La Puma D, Midaglia LS, Mongay-Ochoa N, Nos C, Otero-Romero S, Acevedo BR, Sastre-Garriga J, Tagliani P, Tur C, Vidal-Jordana A, Vilaseca A, Villacieros-Álvarez J, Zabalza A, Rovira À, Tintore M, Comabella M, Rio J, Montalban X, Arrambide G. Refining Treatment Monitoring in Patients With Relapsing Multiple Sclerosis Based on Changes on Neurofilament Light Chain Z-Scores. Neurology. 2026 Sep 22. PMID: 42623577

  10. Olivé C, de Rojas I, Zhang L, Sotolongo-Grau O, Quintela I, García-González P, Puerta R, Montrreal L, Bayón P, Rovira M, Valenzuela A, Capdevila-Bayo M, Muñoz Á, Miguel A, Calm B, Calero M, Rábano A, Belén Pastor A, Del Ser T, Medina M, Carracedo Á, Ramírez A, Molina-Porcel L, Montalbán X, Cano A, Valero S, Marquié M, Sanz P, Sánchez-Juan P, Boada M, Strange B, Fernández MV, Ruiz A. Alzheimer's disease polygenic risk score associates with hippocampal subfield atrophy and immune-related genetic mechanism. Front Aging Neurosci. 2026. PMID: 42620948

  11. Sormani MP, Wiendl H, Montalban X, Oh J. Rethinking multiple sclerosis therapy beyond clinical phenotypes. Brain. 2026 Aug 18. PMID: 42610456

  12. Olsson T, Montalban X, Hohlfeld R, Pozzilli C, Freedman MS, Sprenger T, Fox RJ, Havrdova EK, Lublin F, Raghavan N, Wong J, Vaclavkova A, Pirozek-Lawniczek M, Singh A, Burcklen M, Kappos L. Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 years. Mult Scler Relat Disord. 2026 Oct. PMID: 42561748

  13. Konen FF, Mahmoudi N, Albers LM, Arrambide G, Streichert AL, Haar M, Soldatov A, Bucak E, Jendretzky KF, Nay S, Grote-Levi L, Hegelmaier T, Trebst C, Schwenkenbecher P, Hümmert MW, Pawlitzki M, Sühs KW, Khalil M, Framme C, Petzold A, Meuth SG, Wattjes MP, Haghikia A, Montalban X, Renne J, Skripuletz T. Applying the 2024-revised McDonald criteria for multiple sclerosis using conventional diagnostic tools: a single-centre prospective cohort study in Germany. EClinicalMedicine. 2026 Aug. PMID: 42549016

  14. De Stefano N, Vermersch P, Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Prat A, Leocani L, Schmierer K, Sellebjerg F, Nolting A, Petit C, Guala D, Sponton L, Gardner L, Hodgkinson S. Long-term efficacy of cladribine tablets: Results from the MAGNIFY-MS Extension study. Mult Scler. 2026 Aug 4. PMID: 42548205

  15. Thompson AJ, Lublin FD, Rechtman L, Quinn J, Amato MP, Bebo B, Calabresi PA, Fiol J, Finlayson M, Hawton A, Kuhlmann T, Marrie RA, Moccia M, Montalban X, Panzara M, Smith K, Sormani MP, Strum J, Vickrey BG, Coetzee T, 2025 International Advisory Committee on Clinical Trials in Multiple Sclerosis. Towards a biologically informed description of multiple sclerosis disease course - a roadmap for transition. Nat Rev Neurol. 2026 Oct. PMID: 42547548

  16. Oh J, Barkhof F, Bar-Or A, Ciccarrelli O, Coetzee T, Filippi M, Granziera C, Hacohen Y, Hemmer B, Kantarci OH, Kim HJ, Lebrun-Frenay C, Montalban X, Mowry E, Ontaneda D, Prat A, Reich DS, Rovira À, Sati P, Siva A, Solomon AJ, Sormani MP, Stankoff B, Thompson A, Tintore M, Traboulsee A, van der Walt A, Wiendl H, Calabresi PA. Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria. Nat Med. 2026 Sep. PMID: 42426222

  17. Reinders EM, Masot-Llima A, Otero-Romero S, Carvajal R, Cobo-Calvo Á, Carbonell-Mirabent P, Beltran J, Arévalo MJ, Ariño H, Arrambide G, Auger C, Bollo L, Castilló J, Comabella M, Galán I, García-Sarreón A, Goodman A, Hersh CM, La Puma D, Hua LH, Midaglia L, Mongay-Ochoa N, Mowry EM, Pappolla A, Rodríguez-Acevedo B, Río J, Tagliani P, Vidal-Jordana Á, Vilaseca A, Zabalza A, Pareto D, Nos C, Schoonheim M, Strijbis E, Sastre-Garriga J, Tivarus M, Ziemssen T, Rovira À, Montalban X, Tintoré M, Tur C. Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes. Ann Neurol. 2026 Sep. PMID: 42405485

  18. Hernandez-Rasco F, Ruiz R, de Rojas I, Puerta R, Garcia-Mayor C, Espinosa-Oliva AM, García-Revilla J, Bayon P, Rivera-Ramos A, Oualit FR, Jiménez S, Saez ME, de Pablos RM, Zhao F, Olive C, Sanz P, Montalbán X, Valero S, Cano A, Fernández MV, Wells AM, Cavazos JE, Seshadri S, Boada M, Mañes S, Heneka MT, Vitorica FJ, Ramirez A, Venero JL, Ruiz A. Human IL-34 Deficiency Primes Microglia Toward Alzheimer's Disease-Associated States. medRxiv. 2026 Jun 25. PMID: 42396292

  19. Solomon AJ, Zakaria M, Saylor DR, Viswanathan S, Czarnota-Szałkowska D, Banwell BL, Coetzee T, Montalban X, Hillman N, Shinohara RT, Rijke N, Helme AE, King R. Global Access to Diagnostic Paraclinical Testing Incorporated in the 2024 Revised McDonald Criteria: Disparities and Opportunity. Neurol Clin Pract. 2026 Aug. PMID: 42361331

  20. Cobo-Calvo A, Cuello JP, Monreal E, Villacieros-Álvarez J, Díaz-Troyano N, Otero S, Tur C, García Domínguez JM, Costa-Frossard L, Sainz de la Maza S, Carvajal R, De Miguel Sánchez CJ, Goicochea-Briceño H, Arrambide G, Martínez-Gines ML, Castillo M, Fernández Velasco JI, Vilaseca A, Vidal-Jordana A, Ariño H, Bollo L, Higueras Y, Castilló J, Galán I, Midaglia L, Mongay-Ochoa N, Pappolla A, Río J, Rodríguez-Acevedo B, Zabalza A, Sastre-Garriga J, Meldaña Rivera A, Ruíz-Pérez I, De León-Luis J, Ortega Abad V, Villarrubia N, Rodero-Romero A, Gómez Lozano A, Arribas I, García AM, Comabella M, Rovira Á, Reimundo P, Carbonell M, Herrero J, Carreras E, Montalban X, Ferrer R, Villar ML, Tintore M. Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progression. J Neurol Neurosurg Psychiatry. 2026 Sep 14. PMID: 42342438

  21. Sörensen PS, Zaratin PF, Battaglia MA, Edan G, Samadzadeh S, Leocani L, Becker J, Flores J, Hamuy F, Cristiano E, Patrucco L, Montalbán X, Hartung HP, Comi G, Fernandez OF. Global overview of multiple sclerosis care units: an international cross-sectional survey. Front Neurol. 2026. PMID: 42318246

  22. Oh J, Bar-Or A, Montalban X, Sormani MP, Weber MS, Reich DS. Bruton's tyrosine kinase inhibitors: a new class of multiple sclerosis therapeutics. Lancet Neurol. 2026 Jul. PMID: 42309088

  23. Brochet B, Langdon D, Havrdova EK, Lechner-Scott J, Montalban X, Patti F, Solari A, Alexandri N, Lehn A, Smyk A, Selmaj K, CLARIFY-MS Investigators. Summary of Research: Cognition and Employment Status of People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-Year CLARIFY-MS Study. Neurol Ther. 2026 Aug. PMID: 42271112

  24. Tur C, Susin-Calle S, Otero-Romero S, Carvajal R, Carbonell-Mirabent P, Cobo-Calvo Á, Roos I, Arévalo MJ, Ariño H, Arrambide G, Auger C, Castilló J, Comabella M, Elosua I, Galán I, Masot-Llima A, Midaglia L, Mongay-Ochoa N, Nos C, Pappolla A, Pareto D, Río J, Rodríguez-Acevedo B, Saez de Gordoa E, Vidal-Jordana Á, Vilaseca A, Zabalza A, Rovira À, Sastre-Garriga J, Kalincik T, Montalban X, Tintoré M. Spider-MS: an individualized polyhedral prediction of multiple sclerosis prognosis. Brain. 2026 Sep 7. PMID: 42267539

  25. Cantero-Fortiz Y, Butler C, Montalbán X, Boada M. Cellular senescence in brain aging and neurodegeneration: from molecular mechanisms to translational opportunities. Front Cell Neurosci. 2026. PMID: 42239645

  26. Brochet B, Langdon D, Havrdova EK, Lechner-Scott J, Montalban X, Patti F, Piehl F, Solari A, Hupperts R, Alexandri N, Lehn A, Smyk A, Selmaj K, CLARIFY-MS Investigators. Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two‑year Phase IV CLARIFY‑MS Study. Neurol Ther. 2026 Aug. PMID: 42223882

  27. Giovannoni G, Airas L, Bove R, Cutter GR, Czarnecki M, Drulovic J, Hobart J, Kuhle J, Montalban X, Selmaj KW, Tur C, Wolinsky JS, Baldinotti A, Bonati U, Craveiro L, Giacobino C, Manfrini M, Schneble HM, Stevenson P, Wang Q, Yang K, Oh J, ORATORIO-HAND study group. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study. Lancet. 2026 May 30. PMID: 42208561

  28. Hauser SL, Giovannoni G, Montalban X, Oh J, Bar-Or A, Sormani MP, Weber MS, Stoll S, Nicholas JA, Nehrych T, Bonek R, Selmaj K, Maciejowski M, Zecevic D, Raposo C, Owen R, Bonati U, Madjar K, Harfst E, Wang Q, Raievska A, Manfrini M, Schneble HM, Kappos L, MUSETTE and GAVOTTE Study Groups. Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials. Lancet. 2026 May 30. PMID: 42208560

  29. Carvajal R, Ponzano M, Tur C, Martínez-Gómez X, Esperalba J, Cobo-Calvo Á, Borras-Bemejo B, Bovis F, Ariño H, Arrambide G, Bollo L, Castilló J, Comabella M, Galán I, Hernández-Soria D, Midaglia L, Mongay-Ochoa N, Pappolla A, Ramírez JA, Rodrigo-Pendás JÁ, Rodríguez-Acevedo B, Río J, Vidal-Jordana Á, Vilaseca A, Zabalza A, Sastre-Garriga J, Sormani MP, Montalban X, Tintoré M, Otero-Romero S. Live Attenuated Measles-Mumps-Rubella and Varicella Vaccinations and Multiple Sclerosis Activity. JAMA Netw Open. 2026 May 1. PMID: 42160053

  30. Blazquez-Folch J, Calm B, Hinojosa-Calleja A, García-Gutiérrez F, Alegret M, Muñoz N, Cano A, Fernández MV, Miguel A, Solivar A, De Rojas I, Valenzuela-Seba A, García-González P, Puerta R, Olivé C, Capdevila-Bayo M, Muñoz-Morales Á, Bayón-Buján P, Montrreal L, Orellana A, Ortega G, Sanz-Cartagena P, Rosende-Roca M, Cantero-Fortiz Y, Gurruchaga MJ, Tarraga L, Butler C, Montalban X, Boada M, Ruiz A, Marquié M, Valero S. Listening for Alzheimer's clues: machine learning analysis of multidomain speech features for cognitive impairment screening. Front Aging Neurosci. 2026. PMID: 42157856

  31. Prosperini L, Tortorella C, Barkhof F, Battistini L, Bodini B, Calabrese M, Chard D, Ciccarelli O, De Stefano N, Enzinger C, Filippi M, Kappos L, Kuhle J, Magliozzi R, Rocca MA, Rovira A, Ruggieri S, Sastre-Garriga J, Schoonheim MM, Sormani MP, Stankoff B, Tintoré M, Yousry T, Montalban X, Gasperini C, MAGNIMS network. Rethinking prognosis in multiple sclerosis: a multiaxial perspective. Nat Rev Neurol. 2026 Jul. PMID: 42156973

  32. Montalban X, Oh J, Coetzee T, Thompson AJ. Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis - Authors' reply. Lancet Neurol. 2026 Jun. PMID: 42127922

  33. Sánchez-Ulloa H, Mongay-Ochoa N, Alberich M, Ajdinaj P, Funelli E, Braga N, Rodríguez-Acevedo B, Cabello S, Moncho D, Sceppacuercia S, Auger C, Tintoré M, Montalban X, Vidal-Jordana A, Piella G, Rovira À, Pareto D, Sastre-Garriga J. Assessing optic nerve integrity in optic neuritis with conventional magnetic resonance imaging. AJNR Am J Neuroradiol. 2026 May 12. PMID: 42120102

  34. Peng X, Bjornevik K, Clish CB, Edan G, Freedman MS, Hartung HP, Montalbán X, Sandbrink R, Kuhle J, Barkhof F, Wicklein EM, Kappos L, Ascherio A, Cortese M. Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years. Mult Scler. 2026 Jun. PMID: 42035447

  35. Reyes LVL, Sanchez MÁR, Alsina MA, Sallés MR, Fonseca L, Perna PA, Suárez CC, Pous SS, Sanmillan GL, Tagliani P, Montalban X, Tintoré M, Midaglia L. How misinformation affects family planning choices for women with multiple sclerosis. Patient Educ Couns. 2026 Aug. PMID: 41966603

  36. Schmierer K, Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Sellebjerg F, Vermersch P, Jin H, Sponton L, Chudecka A, Bucello M, Gardner L, De Stefano N. A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study. Neurodegener Dis Manag. 2026 Apr 6. PMID: 41943490

  37. Montalban X, Hohlfeld R, Pozzilli C, Freedman MS, Sprenger T, Fox RJ, Havrdova EK, Lublin F, Huang D, Raghavan N, Wong J, Vaclavkova A, Dukovski J, Linscheid P, Burcklen M, Kappos L. Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study. J Neurol. 2026 Mar 25. PMID: 41879928

  38. Mongay-Ochoa N, Pareto D, Ajdinaj P, Alberich M, Tintore M, Montalban X, Rovira À, Sastre-Garriga J. Assessing the cervical canal area in multiple sclerosis with spinal cord sagittal 2D T2-weighted sequences. MAGMA. 2026 Mar 17. PMID: 41843380

  39. Koc ER, Gluscevic S, Tunc A, Seferoglu M, Bakirtzis C, Samadzadeh S, Selmaj K, Hartung HP, Montalban X, Siva A, ECF Young Investigators/Fellows Initiative. Neuro-behcet's syndrome: epidemiology, mechanisms, and emerging strategies in diagnosis and treatment. Neurol Sci. 2026 Mar 17. PMID: 41840106

  40. Brochet B, Langdon D, Havrdova EK, Lechner-Scott J, Montalban X, Patti F, Piehl F, Solari A, Hupperts R, Alexandri N, Lehn A, Smyk A, Selmaj K, CLARIFY-MS Investigators. Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study. Neurol Ther. 2026 Aug. PMID: 41806309

  41. Puerta R, García-González P, de Rojas I, Capdevila-Bayo M, Olivé C, Muñoz-Morales Á, Bayón-Buján P, Valenzuela A, Yang C, Timsina J, Liu M, Chakkarai S, Sotolongo-Grau O, Calm B, Miguel A, Solivar A, Montrreal L, Martínez M, Khan A, Zhao F, Tantinyà N, Rosende-Roca M, Alegret M, Moreno-Grau S, Fernández MV, Marquié M, Valero S, Cavazos JE, Sanz P, Montalban X, Tàrraga L, Smets B, Boada M, Seshadri S, Sargurupremraj M, Cruchaga C, Cano A, Cabrera-Socorro A, Ruiz A. Human CSF proteogenomics links genetic variation to neurodegenerative disease proteins. medRxiv. 2026 Feb 22. PMID: 41757182

  42. Comabella M, Gutierrez L, Castillo M, Villar LM, Eixarch H, La Puma D, Aroca M, Vilaseca A, Montalban X, Fissolo N. Impact of preanalytical factors on blood CHI3L1 levels. Front Immunol. 2025. PMID: 41704533

  43. García-González P, Puerta R, Dehairs J, Yang C, Wang C, Timsina J, de Rojas I, Olivé C, Valenzuela A, Bayón-Buján P, Rovira M, Montrreal L, Capdevila M, Muñoz-Morales Á, Calm B, Valero S, Alegret M, Marquié M, Global Neurodegeneration Proteomics Consortium (GNPC), Morris JC, Schindler SE, Holtzman DM, Sanz P, Tárraga L, Khan A, Sáez ME, Smets B, Orellana A, Montalbán X, Boada M, Cano A, Liu M, Ali M, Cruchaga C, Swinnen JV, Fernández V, Cabrera-Socorro A, Ruiz A. CSF turnover reshapes biomarker interpretation in neurodegeneration studies. medRxiv. 2026 Feb 3. PMID: 41674604

  44. Bollo L, Pareto D, Tagliani P, Sceppacuercia S, Alberich M, Cabello S, Carbonell P, Villacieros-Álvarez J, Cobo-Calvo À, Tur C, Arrambide G, Carvajal R, Castilló J, Galan I, Mongay-Ochoa N, Pappolla A, Midaglia L, Rodriguez-Acevedo B, Rio J, Vilaseca A, Zabalza A, Comabella M, Auger C, Tintoré M, Sastre-Garriga J, Rovira À, Montalban X, Vidal-Jordana A. Optic nerve imaging with OCT predicts disease progression and monitors brain and spinal atrophy in primary progressive multiple sclerosis. Mult Scler. 2026 Mar. PMID: 41617221

  45. Fissolo N, Benkert P, Vilaseca-Jolonch A, Blanco Y, Hegen H, Berek K, Pérez-Miralles F, Rejdak K, Villar L, Monreal E, Alvarez-Lafuente R, Bachhuber F, Tumani H, Martínez-Yelamos S, Sánchez-López A, García-Merino A, Gutiérrez L, Castillo-Triviño T, Lycke J, Rosenstein I, Téllez N, Furlan R, Lünemann JD, Khalil M, Kuhle J, Montalban X, Comabella M. Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple Sclerosis. Eur J Neurol. 2026 Feb. PMID: 41614569

  46. Fandos N, Pascual-Lucas M, Sarasa L, Terencio J, Sáez ME, Tartari JP, Sanabria Á, Sotolongo-Grau O, Cano A, Tárraga L, Gurruchaga MJ, Ruíz A, Montalban X, Boada M, Alegret M, Marquié M, Allué JA, FACEHBI study group, AMYPAD consortium. Plasma Aβ42/Aβ40 determined by mass spectrometry is associated with longitudinal changes in amyloid accumulation, brain atrophy, and conversion to mild cognitive impairment due to Alzheimer's disease in individuals with subjective cognitive decline: 5-year follow-up of the FACEHBI cohort. J Prev Alzheimers Dis. 2026 Mar. PMID: 41513583

  47. Iza-Achutegui M, Bollo L, Rio J, Marin FN, Montalva AS, Jordana AV, Justribo JC, Zabalza A, Lopez G, Subirana MT, Montalban X. A case of myelopathy due to HTLV-1 infection. Neurol Sci. 2026 Jan 5. PMID: 41486223

  48. Samadzadeh S, Szejko N, Hamadah Y, Tan WY, Gluscevic S, Boldrini V, Ricigliano VAG, Hartung HP, Montalban X, ECF Young Investigators/Fellows Initiative. CAR T cells as novel therapeutic strategy for multiple sclerosis and other neuroimmune disorders. J Neuroinflammation. 2025 Dec 30. PMID: 41470000

  49. Rodero-Romero A, Domínguez-Mozo M, Monreal E, García-Domínguez JM, Villarrubia N, Fernández-Velasco JI, Comabella M, de la Maza SS, Goicochea Briceño H, Chico-García JL, García-Martínez MÁ, Rodriguez-Jorge F, Veiga-Gonzalez JL, Sainz-Amo R, Martínez Ginés ML, Montalban X, Masjuan J, Costa-Frossard L, Álvarez-Lafuente R, Villar LM. New serum soluble factors predicting inflammatory and non-inflammatory disability worsening in multiple sclerosis. Front Immunol. 2025. PMID: 41425552

  50. Keller CW, Stein K, Vilaseca A, Villar LM, Álvarez-Bravo G, Protopapa M, Shin J, Fissolo N, Martínez-Rodríguez JE, Quiroga-Varela A, García-Sarreón A, Gutiérrez L, Midaglia L, Montalban X, Lünemann JD, Comabella M. Reduced CD40 expression in B cell subsets of individuals with radiologically isolated syndrome. Front Immunol. 2025. PMID: 41403945

  51. Hauser SL, Freedman MS, Nakahara J, Paling D, de Seze J, Li J, Abeyewickreme A, Wu M, Sullivan R, Pardo G, Montalban X, Wiendl H. Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosis. Mult Scler Relat Disord. 2026 Jan. PMID: 41380509

  52. Eixarch H, Calvo-Barreiro L, Fissolo N, Boschert U, Hervera A, Comabella M, Montalban X, Espejo C. Cladribine Preserves Normal Central Nervous System Cellular Activity and Promotes Neuroprotection to Oxidative Stress Damage. Int J Mol Sci. 2025 Nov 22. PMID: 41373470

  53. Martinez-Campos E, Robles MA, Horno R, Meza R, Sánchez S, Castilló J, Vidal-Jordana A, Zabalza A, Rodríguez-Acevedo B, Vilaseca A, Arrambide G, Pappolla A, Midaglia L, Galán I, Ariño H, Carvajal R, Mongay N, Cobo-Calvo Á, Comabella M, Tur C, Sastre-Garriga J, Tintoré M, Montalban X, Río J. "Effectiveness and associated factors of response to Fampridine in multiple sclerosis: A prospective observational study from an expert center". Mult Scler Relat Disord. 2026 Jan. PMID: 41319597

  54. Eixarch H, Boutitah-Benyaich I, Plaza J, Rodríguez-Vidal S, Salvadó M, Mancera-Arteu M, Almenara-Fuentes L, Dalmases M, Vives-Pi M, Montalban X, Barneda-Zahonero B, Espejo C. Reprogramming autoimmunity: inducing antigen-specific tolerance via apoptotic mimicry in an experimental model of multiple sclerosis. J Neuroinflammation. 2025 Nov 28. PMID: 41316372

  55. Capdevila-Bayo M, Rossi R, de Rojas I, Puerta R, Guzmán L, Carrasco M, Muñoz-Morales Á, Olivé C, Montrreal L, García-González P, Bayón-Buján P, Miguel-Romero A, Calm B, Sotolongo-Grau O, Orellana A, Tatinya N, Martínez M, Alegret M, Sanz-Cartagena P, Fernández MV, Marquié M, Valero S, Montalbán X, Camins A, Ramírez A, Martí M, Pividori MI, Boada M, Ruiz A, Ettcheto M, Cano A. A peripheral proteomic signature of Alzheimer's disease is identified in the plasma extracellular vesicles of mild cognitive impairment patients from a memory clinic: the BIOPEXAL study. Res Sq. 2025 Nov 1. PMID: 41282153

  56. Cárdenas-Robledo S, Otero-Romero S, García JD, López N, Carbonell-Mirabent P, Rodríguez M, Guío-Sánchez C, Carvajal R, Passarell-Bacradit MA, Sastre-Garriga J, Montalban X, Tintoré M. Clusters of Comorbidities in Multiple Sclerosis and Their Influence on Healthcare Resource Usage. Eur J Neurol. 2025 Nov. PMID: 41190618

  57. Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Krakovich A, Cheng CY, Riolo JV, Pachai C, Thorpe A, DeBoer E, Kappos L, Cohen JA, Cree BA. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial. Mult Scler. 2025 Nov. PMID: 41190505

  58. Ziemssen T, Freedman MS, Bar-Or A, Montalban X, Teunissen CE, Häring DA, Kukkaro P, Merschhemke M, Kieseier BC, Karnik-Henry M, Gee M, Lange S, Merabet E, Chitnis T, Bittner S, Wiendl H, Hauser SL. Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis. Mult Scler. 2025 Nov. PMID: 41159484

  59. Ajdinaj P, Mongay-Ochoa N, Alberich M, Tintore M, Montalban X, Rovira À, Pareto D, Sastre-Garriga J. Long-term impact of spinal cord reserve on disability accumulation in multiple sclerosis. Mult Scler. 2025 Oct. PMID: 41055560

  60. Boutitah-Benyaich I, Eixarch H, Villacieros-Álvarez J, Hervera A, Cobo-Calvo Á, Montalban X, Espejo C. Multiple sclerosis: molecular pathogenesis and therapeutic intervention. Signal Transduct Target Ther. 2025 Oct 2. PMID: 41034190

  61. Saidha S, Green AJ, Leocani L, Vidal-Jordana A, Kenney RC, Bsteh G, Outteryck O, Thompson A, Montalban X, Coetzee T, Petzold A, Paul F, Balcer LJ, Calabresi PA. The use of optical coherence tomography and visual evoked potentials in the 2024 McDonald diagnostic criteria for multiple sclerosis. Lancet Neurol. 2025 Oct. PMID: 40975103

  62. Barkhof F, Reich DS, Oh J, Rocca MA, Li DKB, Sati P, Azevedo CJ, Bagnato F, Calabresi PA, Ciccarelli O, Dwyer MG, DeLuca GC, De Stefano N, Enzinger C, Filippi M, Granziera C, Halper J, Henry RG, Gasperini C, Gauthier S, Kappos L, Laule C, Newsome SD, Montalban X, Morrow SA, Schoonheim MM, Sicotte N, Toosy A, Wilken J, Yousry T, Sastre-Garriga J, Traboulsee A, Ontaneda D, Rovira À, Magnetic Resonance Imaging Network in Multiple Sclerosis, Consortium of Multiple Sclerosis Centers, North American Imaging in Multiple Sclerosis Cooperative MRI guidelines working group. 2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis. Lancet Neurol. 2025 Oct. PMID: 40975102

  63. Montalban X, Lebrun-Frénay C, Oh J, Arrambide G, Moccia M, Amato MP, Amezcua L, Banwell B, Bar-Or A, Barkhof F, Butzkueven H, Ciccarelli O, Chataway J, Cohen JA, Comi G, Correale J, Deisenhammer F, Filippi M, Fiol J, Freedman MS, Fujihara K, Granziera C, Green AJ, Hartung HP, Hellwig K, Kappos L, Kimbrough D, Killestein J, Lublin F, Marignier R, Marrie RA, Miller A, Otero-Romero S, Ontaneda D, Ramanathan S, Reich D, Rocca MA, Rovira À, Saidha S, Salter A, Sastre-Garriga J, Saylor D, Solomon AJ, Sormani MP, Stankoff B, Tintore M, Tremlett H, Van der Walt A, Viswanathan S, Wiendl H, Wildemann B, Yamout B, Zaratin P, Calabresi PA, Coetzee T, Thompson AJ. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025 Oct. PMID: 40975101

  64. Deisenhammer F, Hegen H, Arrambide G, Banwell BL, Coetzee T, Gnanapavan S, Montalban X, Tumani H, Willrich MA, Freedman MS. Positive cerebrospinal fluid in the 2024 McDonald criteria for multiple sclerosis. EBioMedicine. 2025 Oct. PMID: 40967951

  65. Pappolla A, Arrambide G, Montalban X. A paradigm shift away from dissemination in time in multiple sclerosis. Nat Rev Neurol. 2025 Dec. PMID: 40962994

  66. Tseriotis VS, Arrambide G, Carnero Contentti E, Tur C, Wattjes MP, Cortese R, Mitsikostas DD, Grigoriadis N, Adamou A, Chlorogiannis DD, Beltsios E, Magyari M, Truelsen TC, Leocani L, Montalban X. MRI lesion distribution criteria for MS, NMOSD and MOGAD differentiation: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2025 Dec 12. PMID: 40889881

  67. Rodero-Romero A, Fernández-Velasco JI, Monreal E, Sainz-Amo R, Álvarez-Lafuente R, Comabella M, Ramió-Torrentà L, García-Domínguez JM, Villarrubia N, Sainz de la Maza S, Domínguez-Mozo M, Quiroga-Varela A, Chico-García JL, Rodriguez-Jorge F, Veiga-Gonzalez JL, Roldán-Santiago E, Espiño M, Rodríguez-Martín E, Álvarez G, Masjuan J, Montalban X, Costa-Frossard L, Villar LM. Identification of cellular factors associated with inflammation and neurodegeneration in multiple sclerosis. Front Immunol. 2025. PMID: 40852725

  68. Ganjgahi H, Häring DA, Aarden P, Graham G, Sun Y, Gardiner S, Su W, Berge C, Bischof A, Fisher E, Gaetano L, Thoma SP, Kieseier BC, Nichols TE, Thompson AJ, Montalban X, Lublin FD, Kappos L, Arnold DL, Bermel RA, Wiendl H, Holmes CC. AI-driven reclassification of multiple sclerosis progression. Nat Med. 2025 Oct. PMID: 40835969

  69. Vilaseca A, Ariño H, Iacoboni G, Feijóo S, Zabalza A, Fissolo N, Arévalo MJ, Carpio C, Sánchez M, Tintoré M, Comabella M, Montalban X, Barba P, Vidal-Jordana Á. Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy. Eur J Neurol. 2025 Aug. PMID: 40765152

  70. Schmierer K, Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Sellebjerg F, Vermersch P, Jin H, Sponton L, Chudecka A, Gardner L, De Stefano N. Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study. Ther Adv Neurol Disord. 2025. PMID: 40756532

  71. Monreal E, Fernández-Velasco JI, Sainz de la Maza S, Espiño M, Villarrubia N, Roldán-Santiago E, Aladro Y, Cuello JP, Ayuso-Peralta L, Rodero-Romero A, Chico-García JL, Rodríguez-Jorge F, Quiroga-Varela A, Rodríguez-Martín E, Pilo de la Fuente B, Martín-Ávila G, Martínez-Ginés ML, García-Domínguez JM, Rubio L, Llufriu S, Comabella M, Montalban X, Álvarez-Bravo G, Veiga-González JL, Masjuan J, Costa-Frossard L, Villar LM. Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple Sclerosis. Int J Mol Sci. 2025 Jul 18. PMID: 40725145

  72. van der Walt A, Strijbis EMM, Bridge F, Coetzee T, Graves J, Brownlee WJ, Butzkueven H, Marrie RA, Hua LH, Lampe A, Tintore M, Montalban X, Calabresi PA, Barkhof F, International Advisory Committee Clinical Trials in MS Workshop on Ageing and MS members. Advancing multiple sclerosis management in older adults. Nat Rev Neurol. 2025 Aug. PMID: 40702382

  73. Kappos L, Burcklen M, D'Ambrosio D, Fox RJ, Freedman MS, Havrdova EK, Hennessy B, Hohlfeld R, Larbalestier A, Lemle A, Lindenstrøm E, Lublin F, Montalban X, Sidorenko T, Sprenger T, Vaclavkova A, Wuerfel J, Pozzilli C. Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trial. Mult Scler Relat Disord. 2025 Oct. PMID: 40700861

  74. Cohen JA, Arnold DL, DeLuca J, Hartung HP, Kappos L, Comi G, Selmaj K, Steinman L, Bar-Or A, Montalban X, Havrdová EK, Sheffield JK, Pachai C, Cheng CY, Riolo JV, Cree BA. Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials. Mult Scler. 2025 Sep. PMID: 40698614

  75. Cortese M, Peng X, Edan G, Freedman MS, Hartung HP, Montalban X, Sandbrink R, Radü EW, Barkhof F, Wicklein EM, Kappos L, Ascherio A, Bjornevik K, BENEFIT Study Group. Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression. Neurology. 2025 Aug 12. PMID: 40674673

  76. Vilaseca A, Urcelay E, Malhotra S, Castillo M, Aroca M, Vidal-Jordana A, Pappolla A, Carvajal R, Arrambide G, González-Jiménez A, Gómez-Delgado I, Cobo-Calvo A, Mongay-Ochoa N, Rodriguez-Acevedo B, Tur C, Villacieros-Álvarez J, Ariño H, Castilló J, Zabalza A, Midaglia L, La Puma D, Sastre-Garriga J, Tintoré M, Río J, Montalban X, Comabella M. The Variant rs7665090 Is Associated With Interferon-Beta Response in Multiple Sclerosis Patients. Eur J Neurol. 2025 Jul. PMID: 40665510

  77. Coll L, Pareto D, Aparicio-Serrano F, Otero-Romero S, Cobo-Calvo A, Reinders E, Alberich M, Arévalo MJ, Arrambide G, Auger C, Castilló J, Comabella M, Galán I, Midaglia L, Nos C, Novak F, Oliver A, Río J, Rodríguez-Acevedo B, Sastre-Garriga J, Vidal-Jordana Á, Zabalza A, Montalban X, Rovira À, Tintoré M, Lladó X, Tur C. Deep learning to predict progression independent of relapse activity at a first demyelinating event. Brain Commun. 2025. PMID: 40620473

  78. Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Jin H, Chudecka A, Kloetgen A, Lin D, Gardner L, De Stefano N. Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study. Neurol Ther. 2025 Oct. PMID: 40614039

  79. Villacieros-Álvarez J, Sepulveda M, Valls-Carbó A, Fissolo N, Dinoto A, Fernández V, Vilaseca A, Arrambide G, Gutierrez L, Castillo M, Bollo L, Espejo C, Llufriu S, Blanco Y, Armangue T, Álvarez Bravo G, Quiroga-Varela A, Ramió Torrentà L, Cobo-Calvo A, Tintore M, Lünemann JD, Saiz A, Mariotto S, Montalban X, Comabella M. Cerebrospinal 14-3-3 Protein Levels as a Neuroaxonal Biomarker in Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder. Neurol Neuroimmunol Neuroinflamm. 2025 Sep. PMID: 40587836

  80. Abdelhak A, Bachhuber F, Ning K, Benkert P, John Boscardin W, Maleska Maceski A, Schaedelin S, Achtnichts L, Finkener S, Lalive PH, Uginet M, Pot C, Du Pasquier R, Hoepner R, Chan A, Gobbi C, Zecca C, Müller S, Roth P, Granziera C, Chitnis T, Madill E, Weiner HL, Green AJ, Hauser SL, Cree BA, Kümpfel T, Havla J, Skripuletz T, Gingele S, Senel M, Vardakas I, Taranu D, Ziemann U, Kowarik MC, Kleiter I, Hoshi MM, Zettl UK, Haarmann A, Thebault S, Freedman MS, Bergman HP, Iacobaeus E, Khademi M, Ferraro D, Cardi M, Mariotto S, Comabella M, Montalban X, Vilaseca A, Strijbis EM, Wessels MH, Killestein J, Hemmer B, Held F, Sellebjerg F, Højsgaard Chow H, Alvarez-Lafuente R, Domínguez-Mozo MI, Hegen H, Berek K, Deisenhammer F, Thouvenot E, Agherbi H, Rejdak K, Gąsior M, Tzanetakos D, Tzartos JS, Sormani MP, Dujmovic Basuroski I, Arrambide G, Khalil M, Piehl F, Teunissen CE, Kuhle J, Tumani H. Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis. J Neurol Neurosurg Psychiatry. 2025 Oct 15. PMID: 40506119

  81. Fissolo N, Schaedelin S, Villar LM, Lünemann JD, Correale J, Rejdak K, Schwab N, Vilaseca A, Held F, García-Merino A, Bittner S, Trojano M, Furlan R, Tumani H, Pérez-Miralles F, Rosenstein I, Galimberti D, Álvarez-Bravo G, Thouvenot E, Llufriu S, Khoury SJ, Hoepner R, Martínez-Yélamos S, Hegen H, Drulovic J, Téllez-Lara N, Khalil M, Oechtering J, Pérez-Sempere Á, Rodríguez-Antigüedad A, Enrique-Martínez J, Strijbis E, Killestein J, Eichau S, Colombo E, Schaller-Nagengast J, Midaglia L, Sánchez-López AJ, Monreal E, Chan A, Paul F, Rovira À, Tintoré M, Lycke J, Zipp F, Hemmer B, Kuhle J, Montalban X, Comabella M, RIS Study Group. Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome. JAMA Neurol. 2025 Jul 1. PMID: 40455494

  82. Vilaseca A, Vidal-Jordana A, Sceppacuercia S, Calderon W, Arrambide G, Rio J, Tur C, Rodriguez-Acevedo B, Ariño H, Zabalza A, Cobo-Calvo A, Mongay-Ochoa N, Carbonell-Mirabent P, Pappolla A, Carvajal R, Castilló J, Galan I, Midaglia L, Bollo L, Villacieros-Álvarez J, Auger C, Sastre-Garriga J, Tintoré M, Comabella M, Rovira À, Montalban X. Radiologically isolated syndrome: How could we accurately diagnose a subclinical period of multiple sclerosis? Mult Scler. 2025 Jun. PMID: 40443178

  83. Robles-Sánchez MÁ, Amil-Bujan P, Bosch-Farré C, Coll-Martínez C, Arévalo MJ, Anglada-Clofent E, Menéndez-Díaz R, Aroca-Alsina M, Merchan-Ruiz M, Pérez-Hoyos S, Arévalo-Bernabé ÁG, Montalban X, Hernando A, LLufriú S, Peralta-Moncusí S, Brieva L, Ramo-Tello C, Carabí M, Solà-Valls N, Zabay MC, Mañé-Martínez MA, Sastre-Garriga J, Ramió-Torrentà L, Bertran-Noguer C. An expert patient program for people living with multiple sclerosis improves knowledge and empowerment: a pre-test, post-test multicenter implementation study. Front Neurol. 2025. PMID: 40365456

  84. Tur C, Carbonell-Mirabent P, Otero-Romero S, Cobo-Calvo Á, Arévalo MJ, Ariño H, Arrambide G, Auger C, Carvajal R, Castilló J, Comabella M, Galán I, Midaglia L, Nos C, Pappolla A, Pareto D, Río J, Rodríguez-Acevedo B, Saez de Gordoa E, Vidal-Jordana Á, Zabalza A, Sastre-Garriga J, Rovira À, Montalban X, Tintoré M. The Barcelona baseline risk score to predict long-term prognosis after a first demyelinating event: a prospective observational study. Lancet Reg Health Eur. 2025 Jun. PMID: 40291402

  85. Villacieros-Álvarez J, Espejo C, Arrambide G, Dinoto A, Mulero P, Rubio-Flores L, Nieto P, Alcalá C, Meca-Lallana JE, Millan-Pascual J, Martínez-García P, Bernard-Valnet R, González-Suárez I, Orviz A, Téllez R, Navarro Cantó L, Presas-Rodríguez S, Martínez-Yélamos S, Cuello JP, Alonso A, Morales RP, Bravo GÁ, Benyahya L, Trouillet-Assant S, Dyon-Tafan V, Froment Tilikete C, Ruet A, Bourre B, Deschamps R, Papeix C, Maillart E, Kerschen P, Ayrignac X, Rovira À, Auger C, Audoin B, Montalban X, Tintore M, Mariotto S, Cobo-Calvo A, Marignier R. Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Neurol Neuroimmunol Neuroinflamm. 2025 May. PMID: 40203209

  86. Braga N, Aymerich FX, Alonso J, Mongay-Ochoa N, Pareto D, Montalban X, Vidal-Jordana A, Sastre-Garriga J, Rovira À. Synthetic MRI in Progressive MS: Associations with Disability. AJNR Am J Neuroradiol. 2025 Apr 2. PMID: 40174983

  87. Zabalza A, Thompson A, Rotstein DL, Bar-Or A, Montalban X. Multiple sclerosis and COVID-19: interactions and unresolved issues. Lancet Neurol. 2025 Apr. PMID: 40120619

  88. Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Jin H, Chudecka A, Kloetgen A, Lin D, Gardner L, De Stefano N. Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study. Front Immunol. 2025. PMID: 40109340

  89. Carvajal R, Tur C, Borras-Bermejo B, Saylor D, Montalban X, Tintoré M, Otero-Romero S. Vaccination in multiple sclerosis: Tackling challenges and paving the way for effective immunization. Mult Scler. 2025 Jun. PMID: 40071952

  90. Dominguez-Mozo MI, López-Mecández D, Villar LM, Costa-Frossard L, Villarrubia N, Aladro Y, Pilo B, Montalbán X, Comabella M, Casanova-Peño I, González-Suárez I, Martínez-Ginés ML, García-Domínguez JM, García-Calvo E, Machuca-Marcos A, Luque-Garcia JL, Garcia-Martinez MA, Arroyo R, Alvarez-Lafuente R. Short-chain fatty acids in multiple sclerosis: Associated with disability, number of T2 lesions, and inflammatory profile. Ann Clin Transl Neurol. 2025 Mar. PMID: 40033709

  91. Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Jin H, Chudecka A, Kloetgen A, Lin D, Gardner L, De Stefano N. Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study. Front Immunol. 2025. PMID: 39963134

  92. Marignier R, Villacieros-Álvarez J, Espejo C, Arrambide G, Fissolo N, Gutiérrez L, Dinoto A, Mulero P, Rubio-Flores L, Nieto P, Alcalá C, Meca-Lallana JE, Martínez-Garcia P, Millán J, Bernard-Valnet R, González I, Orvíz García A, Tellez R, Navarro L, Presas-Rodríguez S, Romero-Pinel L, Martínez-Yélamos S, Cuello JP, Alonso Torres AM, Piñar R, Álvarez Bravo G, Benyahya L, Trouillet-Assant S, Dyon-Tafani V, Froment Tilikete C, Ruet A, Bourre B, Deschamps R, Papeix C, Maillart E, Kerschen P, Ayrignac X, Rovira A, Auger C, Audoin B, Montalban X, Tintore M, Mariotto S, Cobo-Calvo A. Assessment of neuronal and glial serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease: the MULTIMOGAD study. J Neurol Neurosurg Psychiatry. 2025 Aug 14. PMID: 39939136

  93. Marrodan M, Sao Avilés A, Río J, Cobo-Calvo Á, Fernández V, Pappolla A, Castilló J, Vidal-Jordana Á, Arrambide G, Tur C, Rodríguez-Acevedo B, Zabalza A, Mongay-Ochoa N, Vilaseca A, Rodriguez M, Galán I, Comabella M, Sastre-Garriga J, Tintoré M, Auger C, Rovira À, Montalban X, Midaglia L. Performance of treatment response scoring systems among patients with multiple sclerosis treated with high-efficacy therapies. Mult Scler. 2025 Apr. PMID: 39925147

  94. Vilaseca A, Arranz P, Llaurado A, Zabalza A, Fonseca EG, Medina I, Gómez Lorente MA, Alcalá-González L, Borruel N, Fernández-Forcelledo JL, Ariño H, Armangue T, Montalban X, Graus F, Malagelada C. Novel Approaches to Treatment of Immune-Mediated Chronic Intestinal Pseudo-Obstruction. Neurol Neuroimmunol Neuroinflamm. 2025 Mar. PMID: 39908479

  95. Vilaseca A, Tintoré M, Carbonell-Mirabent P, Rodríguez-Barranco M, Arévalo MJ, Ariño H, Auger C, Bollo L, Carvajal R, Castilló J, Cobo-Calvo A, Comabella M, Fernández V, Galan I, Midaglia L, Mongay-Ochoa N, Nos C, Otero-Romero S, Pappolla A, Rio J, Rodriguez-Acevedo B, Sastre-Garriga J, Sceppacuercia S, Tagliani P, Tur C, Vidal-Jordana A, Villacieros-Álvarez J, Zabalza A, Rovira À, Montalban X, Arrambide G. Uncovering alternative diagnoses in patients with clinical syndromes suggestive of multiple sclerosis: A transversal study from the prospective Barcelona CIS cohort. Mult Scler. 2025 Apr. PMID: 39907218

  96. Cobo-Calvo A, Carbonell-Mirabent P, Tur C, Otero-Romero S, Carvajal R, Arrambide G, Ariño H, Auger C, Villacieros-Álvarez J, Bollo L, Castilló J, Comabella M, Espejo C, Fernández V, Guio-Sánchez C, Galan I, La Puma D, Midaglia LS, Mongay-Ochoa N, Vilaseca A, Arevalo Navines MJ, Nos C, Pappolla A, Rio J, Rodriguez Acevedo B, Zabalza A, Vidal-Jordana A, Pareto D, Sastre-Garriga J, Rovira À, Montalban X, Tintore M. Age-Related Disability Outcomes After a First Demyelinating Event. Neurology. 2025 Feb 25. PMID: 39903901

  97. Dema M, Eixarch H, Hervera A, Castillo M, Villar LM, Montalban X, Espejo C. Disease Aggravation With Age in an Experimental Model of Multiple Sclerosis: Role of Immunosenescence. Aging Cell. 2025 May. PMID: 39894902

  98. Comabella M, Pappolla A, Monreal E, Fissolo N, Sao-Avilés AC, Arrambide G, Carbonell-Mirabent P, Gutierrez L, Cobo-Calvo Á, Tur C, Villacieros-Álvarez J, Vidal-Jordana Á, Castilló J, Galán I, Espiño M, Ariño H, Bollo L, Rodríguez Barranco M, Midaglia LS, Carvajal R, Villarrubia N, Fernández Velasco JI, Rodríguez Acevedo B, Costa Frossard LF, Vilaseca A, Auger C, Zabalza A, Sainz De La Maza S, Mongay-Ochoa N, Río J, Sastre-Garriga J, Rovira À, Tintoré M, Villar LM, Montalban X. Contribution of Blood Biomarkers to Multiple Sclerosis Diagnosis. Neurol Neuroimmunol Neuroinflamm. 2025 Mar. PMID: 39879564

  99. Carvajal R, Guananga-Álvarez D, Tur C, Esperalba J, Rodríguez-Barranco M, Rando-Segura A, Borras-Bermejo B, Cobo-Calvo A, Carbonell-Mirabent P, Zules-Oña R, Rodrigo-Pendas JA, Martínez-Gómez X, Montalban X, Tintore M, Otero-Romero S. Effect of the Number of Vaccine Doses Before Starting Anti-CD20 Therapy on Seroprotection Rates Against Hepatitis B Virus in People With MS. Neurology. 2025 Feb 11. PMID: 39819099

  100. Villacieros-Álvarez J, Espejo C, Arrambide G, Dinoto A, Mulero P, Rubio-Flores L, Nieto P, Alcalá C, Meca-Lallana JE, Millan-Pascual J, Martínez-García P, Bernard-Valnet R, González-Suárez I, Orviz A, Téllez R, Navarro Cantó L, Presas-Rodríguez S, Martínez-Yélamos S, Cuello JP, Alonso A, Piñar Morales R, Álvarez Bravo G, Benyahya L, Trouillet-Assant S, Dyon-Tafan V, Froment Tilikete C, Ruet A, Bourre B, Deschamps R, Papeix C, Maillart E, Kerschen P, Ayrignac X, Rovira À, Auger C, Audoin B, Montalban X, Tintore M, Mariotto S, Cobo-Calvo A, Marignier R. Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Neurol Neuroimmunol Neuroinflamm. 2025 Mar. PMID: 39752619

Publications are shown automatically from PubMed. For this reason incorrect publications may appear or we may be missing some publications.